Message from the CEO

Welcome to Lantheus Medical Imaging and thank you for taking the time to learn more about our company. As a worldwide leader in diagnostic imaging for the past 50 years, we remain committed to our customers and patients and making important investments to continue to elevate the field of medical imaging.  We are excited about the future of our company as we expand on our proud heritage of providing innovative diagnostic imaging products that illuminate the heart and other organs.  We encourage you to learn more about Lantheus Medical Imaging, our people, products and pipeline.

Lantheus Updates

Molybdenum-99 Supply Statement from Lantheus Medical Imaging

As a Technetium-99m (Tc-99m) generator manufacturer, we are one part of a very complex supply chain. We are working with our suppliers to obtain Molybdenum-99 (Mo-99) during this current shortage.  The amount of Mo-99 we receive over the course of this outage will vary day by day. read more

Information on gadofosveset trisodium from Lantheus Medical Imaging, Inc.

Thank you for your interest in our newly acquired product, gadofosveset trisodium (formerly known as Vasovist®). 

At this time, we are not able to provide product. We are establishing the necessary infrastructure to support the commercial launch of the product before the end of the year.  If you have further questions, please send an email to Jocelyn Polk, Corporate Communications, Lantheus Medical Imaging, Inc.

News

6/14/09
SCIENTISTS WHO MADE SIGNIFICANT CONTRIBUTION TO DISCOVERY OF LANTHEUS MEDICAL IMAGING’S CARDIOLITE® HONORED WITH PRESTIGIOUS NUCLEAR MEDICINE AWARD AT SNM ANNUAL MEETING

6/12/09
LANTHEUS MEDICAL IMAGING, INC. TO RECEIVE LEU-DERIVED MO-99 FROM AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (ANSTO) AND BECOMES FIRST TO SUPPLY U.S. MARKET

6/12/09
BARI 2D STUDY PRESENTED AT AMERICAN DIABETES ASSOCIATION
SCIENTIFIC SESSIONS UNDERSCORES UTILITY OF SPECT MYOCARDIAL PERFUSION IMAGING IN IDENTIFYING CARDIOVASCULAR RISK AND EVALUATING TREATMENT OUTCOMES FOR PATIENTS WITH TYPE 2 DIABETES

6/04/09
SPECT MPI WITH CARDIOLITE® USED IN BARI 2D STUDY TO EVALUATE TYPE 2 DIABETES AND CORONARY ARTERY DISEASE TREATMENT STRATEGIES


 Company Spotlight

LANTHEUS MEDICAL IMAGING, INC. TO RECEIVE LEU-DERIVED MO-99 FROM AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (ANSTO) AND BECOMES FIRST TO SUPPLY U.S. MARKET

Supply Arrangement Demonstrates Lantheus’ Commitment to Ensuring Reliable
Global Access to Key Medical Isotope for Medical Imaging Procedures

N. BILLERICA, Mass. and LUCAS HEIGHTS, Australia (June 13, 2009) – Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, has finalized an arrangement with the Australian Nuclear Science and Technology Organisation (ANSTO) to receive molybdenum-99 (Mo-99) produced from low-enriched uranium (LEU) targets in ANSTO’s new OPAL reactor.  This supply arrangement positions Lantheus to be the first company to supply technetium-99m (Tc-99m) derived from LEU to the U.S. market and demonstrates the Company’s commitment to ensuring reliable supply and global access to Tc-99m, the medical isotope used in approximately 80 percent of all nuclear medicine procedures. 

click here for the press release
© 2009 Lantheus Medical Imaging, Inc.
Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
Cardiolite® and DEFINITY® are registered trademarks of Lantheus Medical Imaging, Inc.
Any unlicensed use of these trademarks is expressly prohibited under the U.S. Trademark Act.
Intended for U.S. Residents Only